Healthcare
Live Price
Offline$19.25
+0.00% today
1Y Change
-9.24%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Demant A/S (WILYY) is a Healthcare stock with a market cap of $44.88B and listed on OTC. The stock last traded around $19.25 and down 9.2% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +2.5%, EPS growth of -35.5%, a dividend yield of 0.0%. What stands out right now is revenue +2.5%, EPS -35.5%, free cash flow -3.8% with operating margin 17.6% and ROIC 9.2%. Valuation is more restrained than many high-expectation growth names at P/E 29.0 and price/sales 1.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines WILYY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
WILYY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
WILYY Max Drawdown
-36.88%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for WILYY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$17.9B
-9.1% YoY
FY Net Income
$2.5B
+20.7% YoY
Free Cash Flow
$2.6B
+50.4% YoY
Revenue Growth
+2.5%
EPS Growth
-35.5%
Gross Margin
69.9%
Net Margin
6.7%
Income statement
DKK
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 23.0B | 22.4B | 22.4B | 19.7B | 17.9B |
| Gross Profit | 17.4B | 17.1B | 16.5B | 14.7B | 13.5B |
| Operating Income | 3.9B | 4.4B | 4.1B | 3.2B | 3.7B |
| EBITDA | 5.4B | 5.8B | 5.1B | 4.3B | 4.4B |
| Net Income | 1.5B | 2.4B | 1.8B | 2.1B | 2.5B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
DKK
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.3B | 1.1B | 1.1B | 1.1B | 1.2B |
| Total Assets | 39.1B | 32.5B | 30.5B | 29.9B | 24.9B |
| Total Liabilities | 29.2B | 22.8B | 21.2B | 21.3B | 16.9B |
| Shareholder Equity | 9.8B | 9.6B | 9.3B | 8.6B | 8.0B |
| Total Debt | 21.0B | 15.7B | 14.5B | 15.1B | 11.3B |
| Net Debt | 19.7B | 14.6B | 13.3B | 13.9B | 10.2B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
3.3B
+24.9% YoY
Capital Expenditures
722M
+21.9% YoY
Free Cash Flow
2.6B
+50.4% YoY
Key ratios
Gross Margin
69.9%
Operating Margin
17.6%
Net Margin
6.7%
ROE
16.1%
Debt / Equity
2.39x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.